Cargando…

Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment

BACKGROUND: Immunogenicity of cancer vaccines is impacted by adjuvants and schedule, but systematic assessments of their effects have not been performed. Montanide ISA-51, an incomplete Freund’s adjuvant (IFA), is used in many vaccine trials, but concerns have been raised about negative effects in m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pollack, Karlyn E, Meneveau, Max O, Melssen, Marit M, Lynch, Kevin T, Koeppel, Alexander F, Young, Samuel J, Turner, Stephen, Kumar, Pankaj, Sol-Church, Katia, Mauldin, Ileana S, Slingluff Jr, Craig L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213888/ https://www.ncbi.nlm.nih.gov/pubmed/32350119 http://dx.doi.org/10.1136/jitc-2020-000544

Ejemplares similares

Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma
por: Patel, Sapna P, et al.
Publicado: (2021)

Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine
por: Tran, Christine A, et al.
Publicado: (2023)

The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
por: Meneveau, Max O, et al.
Publicado: (2022)

Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)
por: Slingluff, Jr., Craig L, et al.
Publicado: (2021)

Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4(+) and CD8(+) T cells for immunotherapy of cancer
por: Melssen, Marit M, et al.
Publicado: (2022)

Cytokines and TLR agonists influence the expression of retention integrins CD49a, CD49b and CD103 by T cells
por: Melssen, Marit M, et al.
Publicado: (2015)

Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist
por: Meneveau, Max O, et al.
Publicado: (2021)

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients
por: Melssen, Marit M., et al.
Publicado: (2019)

Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)
por: Vavolizza, Rick D, et al.
Publicado: (2022)

TLR2/6 agonists and IFN-gamma treatment induces favorable immune cell recruiting signatures from melanoma associated with STAT1 and IL-32 signaling
por: Mauldin, Ileana S, et al.
Publicado: (2014)

TLR2/6 agonists and IFNγ synergize to induce melanoma cells to produce T-cell recruiting chemokines
por: Mauldin, Ileana S, et al.
Publicado: (2013)

Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma
por: Lynch, Kevin T, et al.
Publicado: (2021)

Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts
por: Rodriguez, Anthony B., et al.
Publicado: (2021)

Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx
por: Gandhi, Shipra, et al.
Publicado: (2023)

Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
por: Carbone, Carmine, et al.
Publicado: (2021)

Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response
por: Zhang, Lele, et al.
Publicado: (2021)

IMMU-06. Landscape of adaptive immunity of childhood brain cancers
por: Raphael, Itay, et al.
Publicado: (2022)

Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization
por: Jagodinsky, Justin C, et al.
Publicado: (2022)

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors
por: Lemech, Charlotte, et al.
Publicado: (2023)

Barriers to immune cell infiltration in tumors
por: Melssen, Marit M, et al.
Publicado: (2023)

Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
por: Katz, Matthew H G, et al.
Publicado: (2023)

MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma
por: Engelhard, Victor H, et al.
Publicado: (2020)

In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
por: Jenner, Adrianne L, et al.
Publicado: (2021)

Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei
por: Flatmark, Kjersti, et al.
Publicado: (2021)

Incomplete response in late-life depression: getting to remission
por: Lenze, Eric J., et al.
Publicado: (2008)

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
por: Ellingsen, Espen Basmo, et al.
Publicado: (2022)

Effect of lipoarabinomannan from Mycobacterium avium subsp avium in Freund's incomplete adjuvant on the immune response of cattle
por: Colavecchia, S.B., et al.
Publicado: (2012)

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
por: Slingluff, Craig L, et al.
Publicado: (2021)

Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells
por: Pietà, Anna Dalla, et al.
Publicado: (2021)

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
por: Overman, Michael, et al.
Publicado: (2020)

Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
por: Abe, Shinya, et al.
Publicado: (2022)

T057: Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume
por: Lynch, Ryan C., et al.
Publicado: (2022)

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
por: Nghiem, Paul, et al.
Publicado: (2021)

Microcrystalline Tyrosine and Aluminum as Adjuvants in Allergen-Specific Immunotherapy Protect from IgE-Mediated Reactivity in Mouse Models and Act Independently of Inflammasome and TLR Signaling
por: Leuthard, Deborah S., et al.
Publicado: (2018)

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
por: van den Berg, Joost H, et al.
Publicado: (2020)

Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant
por: Koh, Yi T, et al.
Publicado: (2006)

Cell Recruitment and Cytokines in Skin Mice Sensitized with the Vaccine Adjuvants: Saponin, Incomplete Freund’s Adjuvant, and Monophosphoryl Lipid A
por: Vitoriano-Souza, Juliana, et al.
Publicado: (2012)

Phase 2 study of pembrolizumab in patients with advanced rare cancers
por: Naing, Aung, et al.
Publicado: (2020)

Immune profile of an atypical EAE model in marmoset monkeys immunized with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund’s adjuvant
por: Jagessar, S. Anwar, et al.
Publicado: (2015)

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
por: Cortellini, Alessio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pc1jehsmcfakkeecaklg3udp8r